Protagonist Therapeutics(PTGX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PTGX Protagonist Therapeutics

Trading 10-13 10:35:22 EDT

141.39

-3.49

-2.41%

High146.00	Low140.45	Vol186.60K
Open146.00	D1 Closing144.88	Amplitude3.83%
Mkt Cap9.15B	Tradable Cap8.93B	Total Shares64.71M
T/O26.49M	T/O Rate0.30%	Tradable Shares63.17M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PTGX","market":"US","secType":"STK","nameCN":"Protagonist Therapeutics","latestPrice":141.385,"timestamp":1791902118654,"preClose":144.88,"halted":0,"volume":186603,"delay":0,"changeRate":-0.02412341247929324,"floatShares":63165959,"shares":64708285,"eps":1.03,"marketStatus":"Trading","change":-3.495,"latestTime":"10-13 10:35:22 EDT","open":146,"high":146,"low":140.45,"amount":26494582.50507,"amplitude":0.038308,"askPrice":142.08,"askSize":19,"bidPrice":140.65,"bidSize":10,"shortable":3,"etf":0,"ttmEps":1.03,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791921600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1470888000000,"exchange":"NASDAQ","adjPreClose":144.88,"preHourTrading":{"tag":"盘前","latestPrice":146,"preClose":144.88,"latestTime":"09:29 EDT","volume":5014,"amount":727559.6789599999,"timestamp":1791898199999,"change":1.12,"changeRate":0.007731,"amplitude":0.06005},"postHourTrading":{"tag":"盘后","latestPrice":144.88,"preClose":144.88,"latestTime":"19:30 EDT","volume":15575,"amount":2256618.01,"timestamp":1791847803406,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.305025,"impliedVol":0.4332,"impliedVolPercentile":0.2829},"requestUrl":"/m/hq/s/PTGX/tweets","defaultTab":"tweets","newsList":[{"id":"2674808843","title":"Protagonist Therapeutics Coverage Assumed by Leerink Partners at Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2674808843","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674808843?lang=en_us&edition=fundamental","pubTime":"2026-10-12 21:03","pubTimestamp":1791810180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PTGX/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674729988","title":"UBS Initiates Coverage on Protagonist Therapeutics With Buy Rating, $184 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2674729988","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674729988?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:38","pubTimestamp":1791805086,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics (PTGX) has an average rating of buy and mean price target of $159.36, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674879345","title":"Protagonist Therapeutics, Inc. : Leerink Partners Assumes Coverage with Outperform Rating; Target Price $190","url":"https://stock-news.laohu8.com/highlight/detail?id=2674879345","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674879345?lang=en_us&edition=fundamental","pubTime":"2026-10-12 18:09","pubTimestamp":1791799776,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nFWN45Y1XM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674875797","title":"Protagonist Therapeutics initiated with a Buy at UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2674875797","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674875797?lang=en_us&edition=fundamental","pubTime":"2026-10-12 17:35","pubTimestamp":1791797711,"startTime":"0","endTime":"0","summary":"UBS initiated coverage of Protagonist Therapeutics (PTGX) with a Buy rating and $184 price target The firm sees “underappreciated commercial potent...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/protagonist-therapeutics-initiated-with-a-buy-at-ubs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/protagonist-therapeutics-initiated-with-a-buy-at-ubs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672407627","title":"Protagonist Therapeutics (PTGX) Could Be 25% Undervalued On Its Royalty Backed Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2672407627","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672407627?lang=en_us&edition=fundamental","pubTime":"2026-10-03 14:23","pubTimestamp":1791008581,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics (PTGX) moved slightly higher at the latest close, with the share price at US$140.06. This has drawn attention to how investors are weighing its clinical pipeline, recent returns, and current valuation profile.\nRecent trading tells a mixed story for Protagonist Therapeutics. In the short term, the shares have eased, with a 7 day share price return of 1.27% lower and a 30 day share price return of 4.12% lower. However, the year to date share price return of 60.66% and a...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/protagonist-therapeutics-ptgx-could-be-25-undervalued-on-its","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/protagonist-therapeutics-ptgx-could-be-25-undervalued-on-its","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PTGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672460257","title":"Protagonist Therapeutics CFO Ali Asif Disposes of Common Shares Worth $8,314,337.28","url":"https://stock-news.laohu8.com/highlight/detail?id=2672460257","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672460257?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:10","pubTimestamp":1790971856,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics CFO Ali Asif disposes of common shares worth $8,314,337.28Protagonist Therapeutics CFO Asif Ali sold 58,629 shares on Sept. 30, 2026 at USD 141.77–USD 141.78.He exercised stoc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL6QDdfL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Protagonist Therapeutics CFO Ali Asif Disposes of Common Shares Worth $8,314,337.28","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670418484","title":"The Peptide Boom That Isn't About Your Muscles - Heard on the Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2670418484","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670418484?lang=en_us&edition=fundamental","pubTime":"2026-09-25 17:30","pubTimestamp":1790328600,"startTime":"0","endTime":"0","summary":"Peptides are everywhere lately. Influencers inject them for muscle and recovery, and the Food and Drug Administration could soon allow these products to be sold by compounding pharmacies.While the mar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666512173","title":"Protagonist Therapeutics CEO Dinesh V. Patel Disposes of Common Shares Worth USD 18.25 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2666512173","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666512173?lang=en_us&edition=fundamental","pubTime":"2026-09-11 09:18","pubTimestamp":1789089497,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics CEO Dinesh V. Patel disposes of common shares worth USD 18.25 millionProtagonist Therapeutics President, CEO, director Dinesh V. Patel filed a Form 4 reporting option exercise","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDLwWhh3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Protagonist Therapeutics CEO Dinesh V. Patel Disposes of Common Shares Worth USD 18.25 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377208","title":"Protagonist Therapeutics announces $300M share repurchase program","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377208","media":"TIPRANKS","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377208?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:35","pubTimestamp":1788899758,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics (PTGX) announced that its board of directors has authorized a share repurchase program under which the company may repurch...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/protagonist-therapeutics-announces-300m-share-repurchase-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/protagonist-therapeutics-announces-300m-share-repurchase-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666031372","title":"Protagonist Therapeutics Launches USD 300 Million Share Buyback Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2666031372","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666031372?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:05","pubTimestamp":1788897932,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics launches USD 300 million share buyback programProtagonist Therapeutics launched a share repurchase program for up to USD 300 million of outstanding common stock.Funding planne","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDLc74SRP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0683600562.USD","BK4533","LU1551013342.USD","FHLC","BMED","LU2750360641.GBP","XLV","LU2468319806.SGD","MEDX","LU1066051225.USD","SGXZ80539844.SGD","IE00BGHQF631.EUR","IE00B42XCP33.USD","IYH","VHT","LU1267930813.SGD","JDOC","LU1506573853.SGD","RXL","LU1778281490.HKD","TRUH","LU1057294990.SGD","SG9999001440.SGD","IE0002141913.USD","LU1145028129.USD","IE00B4R5TH58.HKD","IE0009355771.USD","IE00BFXG1179.USD","BK4007","JNJ","IXJ","LU0058720904.USD","LU1244550221.USD","LU0689472784.USD","LU2602419157.SGD","LU2487616109.SGD","LU1718418525.SGD","PTGX","BK4504","BK4588","IE00B19Z3B42.SGD","IHE","LU2430703095.HKD","SG9999001176.SGD","GDOC","FTXH","LU1032955483.USD","LU0820562030.AUD","PJP","IE00BDGV0183.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664815289","title":"Protagonist Therapeutics CEO Patel Joins Fireside Chats at Two Investment Bank Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664815289","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664815289?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:05","pubTimestamp":1788347129,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics CEO Patel joins fireside chats at two investment bank conferencesProtagonist Therapeutics will take part in the Citi Biopharma Back to School Conference in New York on Sept. 9","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDLrhtgt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TFNS","LU2125154778.USD","BK4207","LU0648001328.SGD","LU0098860793.USD","LU0314106906.USD","LU1201861249.SGD","LU1366192091.USD","LU1244550577.SGD","IYF","LU0052756011.USD","LU0170899867.USD","LU1144417596.USD","LU0130517989.USD","LU1506573853.SGD","LU0320765646.SGD","LU2236285917.USD","LU0128525689.USD","LU1162221912.USD","BK4139","LU1244550221.USD","LU0980610538.SGD","LU1668664300.SGD","LU1074936037.SGD","LU1244550494.USD","LU2360032135.SGD","BK4534","IE00BSNM7G36.USD","PTGX","FTXO","LU2417539215.USD","LU1267930227.SGD","BK4566","LU1791807156.HKD","LU2462157665.USD","LU2125154935.USD","BK4504","BK4559","LU0310800965.SGD","LU0477156953.USD","LU0203345920.USD","LU0130102774.USD","LU0162691827.USD","BK4588","LU0106831901.USD","LU0072461881.USD","LU2456880835.USD","BK4585","LU0203347892.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664286523","title":"Protagonist Therapeutics Price Target Raised to $180.00/Share from $153.00 by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2664286523","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664286523?lang=en_us&edition=fundamental","pubTime":"2026-09-02 02:54","pubTimestamp":1788288840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PTGX/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664859516","title":"Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), Teladoc (TDOC) and Protagonist Therapeutics (PTGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664859516","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664859516?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:10","pubTimestamp":1788264606,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Viridian Therapeutics (VRDN), Teladoc (TDOC) and P...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-viridian-therapeutics-vrdn-teladoc-tdoc-and-protagonist-therapeutics-ptgx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-viridian-therapeutics-vrdn-teladoc-tdoc-and-protagonist-therapeutics-ptgx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861558580.USD","BK4548","BK4585","BK4534","XBI","XLV","LU1861559042.SGD","BK4588","BK4137","PTGX","TDOC","HCSG","BK4504","BK4167","LU0029874061.USD","LU0128526141.USD","LABU","BK4567","BK4581","BK4139","VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664881570","title":"Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881570","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664881570?lang=en_us&edition=fundamental","pubTime":"2026-09-01 08:30","pubTimestamp":1788222626,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Palvella Therapeutics (PVLA), Protagonist Therapeuti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-palvella-therapeutics-pvla-protagonist-therapeutics-ptgx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-palvella-therapeutics-pvla-protagonist-therapeutics-ptgx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4581","BK4137","PVLA","BK4585","PTGX","LABU","BK4588","LU0029874061.USD","BK4139","XBI","XLV","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664000163","title":"Protagonist Therapeutics' Mimrylo Holds Commercial Potential After FDA Approval, Truist Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2664000163","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664000163?lang=en_us&edition=fundamental","pubTime":"2026-09-01 02:53","pubTimestamp":1788202412,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics  could have attractive commercial potential for Mimrylo following the US Food and Drug Administration's approval for treating polycythemia vera, a rare blood cancer, Truist Securities said in a note Monday.Mimrylo label's lack of a black-box warning, fatigue improvement and self-administration could support patient adoption, Truist said.The brokerage also expects payer approval given Mimrylo's potential to reduce the recurring burden of phlebotomies, while noting the treatment can be added to patients' existing PV therapy.Truist also expects Mimrylo to have three to four years of \"uncontested commercialization.\"Truist maintained a buy rating with a $170 price target.Price: 144.97, Change: +0.64, Percent Change: +0.44","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","BK4585","PTGX","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664006070","title":"Citigroup Raises Protagonist Therapeutics Price Target to $182 From $175, Buy Rating Kept","url":"https://stock-news.laohu8.com/highlight/detail?id=2664006070","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664006070?lang=en_us&edition=fundamental","pubTime":"2026-09-01 02:40","pubTimestamp":1788201654,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics (PTGX) has an average rating of buy and mean price target of $159.36, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664000358","title":"Protagonist Therapeutics price target raised to $170 from $165 at Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2664000358","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664000358?lang=en_us&edition=fundamental","pubTime":"2026-09-01 02:15","pubTimestamp":1788200133,"startTime":"0","endTime":"0","summary":"Citizens raised the firm’s price target on Protagonist Therapeutics (PTGX) to $170 from $165 and keeps an Outperform rating on the shares after the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/protagonist-therapeutics-price-target-raised-to-170-from-165-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/protagonist-therapeutics-price-target-raised-to-170-from-165-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CFG","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663800423","title":"Protagonist Therapeutics' Own Pipeline Seen as Main Long-Term Growth Driver, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2663800423","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663800423?lang=en_us&edition=fundamental","pubTime":"2026-08-31 23:29","pubTimestamp":1788190151,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics'  future growth will hinge more on its wholly owned programs than on its newly approved partner therapy, with the company's first clinical readouts from its proprietary pipeline expected in H1 2027. Wedbush Securities said Monday in a report.Wedbush highlighted PN-8047, an oral version of rusfertide, a treatment recently approved for polycythemia vera and commercialized by Takeda Pharmaceutical . PN-8047 appears similarly potent and may move into a phase 2 study in 2027 if early safety and iron-lowering data are positive, the report said.Protagonist's cash position is strengthened by payments tied to rusfertide's regulatory approval, including a $200 million opt-out fee and a $75 million milestone, along with similar payments from Johnson & Johnson  for icotyde, an oral anti-inflammatory drug being developed for psoriasis and other immune conditions, the report said.Wedbush maintained its outperform rating on Protagonist stock with a $173 price target.Price: 14","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MEDX","LU1894683264.USD","LU1074936037.SGD","IHE","IE0034235303.USD","IE00BDGV0183.EUR","LU1221951046.USD","LU1585245621.USD","LU2430703178.SGD","FTXH","IXJ","BMED","JDOC","GDOC","LU0426412945.USD","TRUH","LU0795875169.SGD","LU1145028129.USD","LU2750360641.GBP","VHT","LU1244550494.USD","IYH","LU0640476718.USD","LU0320765646.SGD","LU1430594728.SGD","FHLC","LU0432979614.USD","PTGX","IE00BLSP4452.SGD","PJP","IE000SO60NU8.SGD","LU1196500208.SGD","RXL","SG9999013999.USD","IE000BZT7R73.USD","LU1032466523.USD","XLV","IE00BFTCPJ56.SGD","JNJ","BK4139","IE0002270589.USD","LU0234572021.USD","LU0122379950.USD","SG9999002232.USD","SG9999001176.SGD","LU2602419157.SGD","SGXZ57979304.SGD","TAK","LU2347655156.SGD","LU2430703251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663400108","title":"Protagonist Therapeutics is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2663400108","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663400108?lang=en_us&edition=fundamental","pubTime":"2026-08-31 22:53","pubTimestamp":1788187980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PTGX/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663034360","title":"Protagonist Therapeutics (PTGX) Receives a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2663034360","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663034360?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:35","pubTimestamp":1788179720,"startTime":"0","endTime":"0","summary":"In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Protagonist Therapeutics, with a price target of $170.00. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/protagonist-therapeutics-ptgx-receives-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/protagonist-therapeutics-ptgx-receives-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.protagonist-inc.com","stockEarnings":[{"period":"1week","weight":0.0302},{"period":"1month","weight":-0.0223},{"period":"3month","weight":0.1037},{"period":"6month","weight":0.3741},{"period":"1year","weight":0.6653},{"period":"ytd","weight":0.6588}],"compareEarnings":[{"period":"1week","weight":0.0042},{"period":"1month","weight":0.0181},{"period":"3month","weight":0.0349},{"period":"6month","weight":0.1117},{"period":"1year","weight":0.1915},{"period":"ytd","weight":0.141}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.030975},{"month":2,"riseRate":0.5,"avgChangeRate":0.004927},{"month":3,"riseRate":0.5,"avgChangeRate":0.077907},{"month":4,"riseRate":0.2,"avgChangeRate":-0.1188},{"month":5,"riseRate":0.7,"avgChangeRate":0.186258},{"month":6,"riseRate":0.8,"avgChangeRate":0.107488},{"month":7,"riseRate":0.6,"avgChangeRate":0.013966},{"month":8,"riseRate":0.8,"avgChangeRate":0.154012},{"month":9,"riseRate":0.454545,"avgChangeRate":0.000534},{"month":10,"riseRate":0.454545,"avgChangeRate":0.038557},{"month":11,"riseRate":0.6,"avgChangeRate":0.076941},{"month":12,"riseRate":0.5,"avgChangeRate":0.014044}],"exchange":"NASDAQ","name":"Protagonist Therapeutics","nameEN":"Protagonist Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Protagonist Therapeutics(PTGX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Protagonist Therapeutics(PTGX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Protagonist Therapeutics,PTGX,Protagonist Therapeutics股票,Protagonist Therapeutics股票老虎,Protagonist Therapeutics股票老虎国际,Protagonist Therapeutics行情,Protagonist Therapeutics股票行情,Protagonist Therapeutics股价,Protagonist Therapeutics股市,Protagonist Therapeutics股票价格,Protagonist Therapeutics股票交易,Protagonist Therapeutics股票购买,Protagonist Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Protagonist Therapeutics(PTGX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Protagonist Therapeutics(PTGX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}